Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. operates as a clinical stage biopharmaceutical company that focuses on research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical tr… Read more
Vivoryon Therapeutics N.V. - Asset Resilience Ratio
Vivoryon Therapeutics N.V. (0R3M) has an Asset Resilience Ratio of 32.44% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2023)
This chart shows how Vivoryon Therapeutics N.V.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Vivoryon Therapeutics N.V.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.00 Million | 32.44% |
| Total Liquid Assets | €10.00 Million | 32.44% |
Asset Resilience Insights
- Very High Liquidity: Vivoryon Therapeutics N.V. maintains exceptional liquid asset reserves at 32.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vivoryon Therapeutics N.V. Industry Peers by Asset Resilience Ratio
Compare Vivoryon Therapeutics N.V.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Annual Asset Resilience Ratio for Vivoryon Therapeutics N.V. (2010–2023)
The table below shows the annual Asset Resilience Ratio data for Vivoryon Therapeutics N.V..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 32.51% | €10.02 Million | €30.83 Million | +29.59pp |
| 2013-12-31 | 2.92% | €186.00K | €6.37 Million | +2.90pp |
| 2012-12-31 | 0.02% | €2.00K | €10.01 Million | -5.36pp |
| 2011-12-31 | 5.38% | €1.03 Million | €19.09 Million | +5.22pp |
| 2010-12-31 | 0.17% | €27.00K | €15.97 Million | -- |